Targeting Stealth Liposomes to Cancer Cells
Author Information
Author(s): D Goren, AT Horowitz, S Zalipsky, MC Woodle, Y Yarden, A Gabizon
Primary Institution: Hadassah Hebrew University Hospital
Hypothesis
Can stealth liposomes conjugated with antibodies effectively target erbB-2 positive cancer cells?
Conclusion
The study found that while antibody-targeted liposomes showed increased binding to erbB-2 positive cells, they did not enhance therapeutic efficacy compared to non-targeted liposomes.
Supporting Evidence
- Targeted liposomes showed a 16-fold increase in binding to erbB-2 positive cells compared to non-targeted liposomes.
- Both targeted and non-targeted liposomes enhanced doxorubicin concentration in tumors compared to free drug administration.
- Therapeutic efficacy was similar for both targeted and non-targeted liposomes.
Takeaway
Researchers wanted to see if special liposomes could deliver medicine better to cancer cells. They found that even though the liposomes stuck to the cancer cells well, they didn't work better than regular ones.
Methodology
The study involved in vitro binding assays, cytotoxicity tests, and biodistribution studies in nude mice with implanted tumors.
Limitations
The study did not demonstrate improved therapeutic efficacy of targeted liposomes over non-targeted ones despite their increased binding affinity.
Participant Demographics
Nude mice bearing subcutaneous implants of N-87 tumors were used for in vivo studies.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website